Quantum BioPharma has completed the 90-day oral toxicity and toxicokinetic studies for its Multiple Sclerosis (MS) drug, Lucid-21-302 (Lucid-MS). These studies are a crucial step towards submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of the year. The company aims for Lucid-MS to become a first-in-class treatment for MS.
The completion of these preclinical studies is a significant milestone for Quantum BioPharma. It demonstrates the company’s commitment to advancing Lucid-MS through the regulatory pathway, bringing them closer to clinical trials in humans. This progress could potentially attract further investment and partnerships, bolstering the company’s position in the MS treatment landscape. For patients, the successful completion of these studies offers hope for a new therapeutic option, especially given Lucid-MS’s preclinical potential to prevent and reverse myelin degradation, a key factor in MS progression.
The 90-day toxicity and toxicokinetic studies provide essential safety and pharmacokinetic data required for the IND application. These studies assess the drug’s potential adverse effects and its absorption, distribution, metabolism, and excretion in the body. This information is critical for determining safe and effective dosing regimens in future clinical trials.
This advancement positions Quantum BioPharma to potentially initiate Phase 2 clinical trials for Lucid-MS in MS patients. The upcoming IND submission is a pivotal step towards validating the drug’s potential and could significantly impact the company’s future growth trajectory. Positive clinical trial results could transform the MS treatment market and offer patients a new mechanism of action to combat the debilitating effects of the disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
